18860855. USE OF SHP2 INHIBITORS FOR INHIBITING SENESCENCE (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
USE OF SHP2 INHIBITORS FOR INHIBITING SENESCENCE
Organization Name
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventor(s)
Armelle Yart of Toulouse Cedex 4 FR
Laurène Mazeyrie of Toulouse FR
Jean-Philippe Pradere of Toulouse FR
USE OF SHP2 INHIBITORS FOR INHIBITING SENESCENCE
This abstract first appeared for US patent application 18860855 titled 'USE OF SHP2 INHIBITORS FOR INHIBITING SENESCENCE
Original Abstract Submitted
According to the WHO, the population aged 60 and over will have doubled by 2050. Unfortunately, aging comes along with an explosion of aging-associated disorders, such as metabolic and cardiovascular diseases, bone and muscle weakening, cognitive dysfunction, that all contribute to the loss of functional capacities, leading to frailty and dependence. Now, the inventors reveal a premature aging phenotype, associating metabolic defects and muscle weakness, in a mouse model of Noonan Syndrome. Both clinical traits are linked to myeloid cells dysfunction and increased senescence, highlighting the role of SHP2 hyperactivation in the onset of aging-associated diseases. Thus the present invention relates to the use of SHP2 inhibitors for inhibiting senescence.